✦ LIBER ✦

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response

✍ Scribed by Rosenberg, S.A.; Yang, J.C.; White, D.E.; Steinberg, S.M.

Book ID: 123266076
Publisher: Lippincott Williams and Wilkins
Year: 1999
Tongue: English
Weight: 107 KB
Volume: 162
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(05)68669-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Initial Clinical Response Predicts Outco

Initial Clinical Response Predicts Outcome and Is Associated With Dose Schedule in Metastatic Melanoma and Renal Cell Carcinoma Patients Treated With High-Dose Interleukin 2

✍ Kathryn Spanknebel; Kenneth Y. Cheung; John Stoutenburg; Karl Hurst-Wicker; Char 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 133 KB

Initial clinical response predicts outco

Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin-2

✍ K. Spanknebel; K. Hurst-Wicker; Y. K. Cheung; C. Hesdorffer; G. DeRaffele; H. Ka 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 148 KB

Trends in the safety of high dose bolus

Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer

✍ Udai S. Kammula; Donald E. White; Steven A. Rosenberg 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## BACKGROUND. Administration of recombinant high dose interleukin-2 (IL-2) can mediate tumor regression in patients with metastatic melanoma and renal carcinoma. Significant trends in the safety of high dose IL-2 administration at a single institution over a 12-year study period were reviewed. #

473 Interleukin 2 (RIL2) in the treatmen

473 Interleukin 2 (RIL2) in the treatment of metastatic renal cell carcinoma-durable complete response with long term follow-up

✍ K.H.M. Rowley; D. Mort; C.W. Keen; M.D. Mason 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 162 KB

1101 Identification of a potential molec

1101 Identification of a potential molecular marker of response to high-dose interleukin-2 in metastatic renal cell carcinoma patients

✍ Jacobs, C.D.; Lipowska-Bhalla, G.; Dalal, N.; Thistlethwaite, F.; Hawkins, R.E.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Patients with metastatic melanoma or ren

Patients with metastatic melanoma or renal cancer who have not achieved a response after 2 cycles of high-dose bolus aldesleukin [interleukin-2]

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB